1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Characteristics of patients with one treated vertebral compression fracture (VCF) and no new VCF or pain at another untreated level during follow-up (subgroup A) and the remaining patients (subgroup B)
Total Group Subgroup A Subgroup B P Value
No of patients 64 31 33
Median age (y) (range) 70 (47–88) 70 (47–88) 70 (51–88) .5
    Mean age (y) 69 68 70 
Women (%) 49 (77) 24 (77) 8 (24) .9
No. of VCF treated by PV 89 31 59 -
Median age in months of treated VCF (range) 4 (2–48) 4 (2–13) 4 (2–48) .3
    Mean age 5.5 4.5 6.0 
Extent bone marrow edema in treated VCF 
    Minor (1%–24%) 6 6 5 
    Moderate (25%–74%) 27 26 28 .95
    Severe (75%–100%) 67 68 67 
Shape treated VCF (%)
    Wedge 61 68 57 
    Biconcave 39 32 43 .3
Grade treated VCF (%) 
    Mild 28 26 29 
    Moderate 33 39 29 .7
    Severe 39 35 41 
Median injected cement volume (cc) (range) 3.0 (1.0–4.5) 3.0 (1.2–4.5) 2.6 (0.8–4.0) .01
    Mean 2.6 3.0 2.4 
Median initial VAS for pain (range) 9.0 (4–10) 8.0 (4–10) 10 (6–10) .02
    Mean 8.7 8.2 9.1 
Initial pain medication (%)
    No 11 13 9 
    Paracetamol 12 13 12 0.2
    NSAID 28 39 18 
    Operative 49 35 61 
Patients with multiple treated VCF (%) 19 (29) - 19 (58) -
Patients with new VCF after PV (%) 17 (26) - 17 (52) -
Patients with pain at another untreated level 7 (11) - 7 (21) -
After PV, but without new VCF (%) 
Note: — PV indicates percutaneous vertebroplasty; VAS, visual analog score; NSAID, nonsteroid antiinflammatory drugs.
P values indicate differences in subgroups A and B.